Mylan gets FDA OK to market generic version of Norvasc

Share this article:
Generic drug maker Mylan received final FDA approval for a generic version of Pfizer's blockbuster blood-pressure medicine Norvasc.
Mylan said in a statement that since it was the first generic company to file with the FDA on all strengths of Norvasc, the company is eligible for 180 days of market exclusivity.
The approval covers tablets of Norvasc's active ingredient, amlodipine besylate, in strengths of 2.5 milligrams, 5 milligrams, and 10 milligrams.
Mylan said the exclusivity period will begin with its launch of the product or with the resolution of a patent lawsuit between it and Pfizer, whichever comes first.
Two patents protect Norvasc -- the first protects the amlodipine molecule, and the second protects the besylate salt formulation of the molecule.
The patents expire Jan. 31, 2007, and Sept. 25, 2007, respectively.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.